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A bs tr ac t
Background
An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary 
artery disease that is highly heritable. The genetic determinants of the Lp(a) lipopro-
tein level and their relevance for the risk of coronary disease are incompletely under-
stood.
Methods
We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) 
in 2100 candidate genes to test for associations in 3145 case subjects with coronary 
disease and 3352 control subjects. Replication was tested in three independent popu-
lations involving 4846 additional case subjects with coronary disease and 4594 con-
trol subjects.
Results
Three chromosomal regions (6q26–27, 9p21, and 1p13) were strongly associated with 
the risk of coronary disease. The LPA locus on 6q26–27 encoding Lp(a) lipoprotein 
had the strongest association. We identified a common variant (rs10455872) at the 
LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval 
[CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio 
of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an in-
creased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines 
the number of kringle IV–type 2 repeats), and a small Lp(a) lipoprotein size. Repli-
cation studies confirmed the effects of both variants on the Lp(a) lipoprotein level 
and the risk of coronary disease. A meta-analysis showed that with a genotype score 
involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 
to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After 
adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype 
score and the risk of coronary disease was abolished.
Conclusions
We identified two LPA variants that were strongly associated with both an increased 
level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings 
provide support for a causal role of Lp(a) lipoprotein in coronary disease.
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Genomewide association studies have identified several novel susceptibil-ity loci for coronary artery disease,1-4 but 
it is likely that only common variants can be de-
tected in this way.5,6 Moreover, loci that are iden-
tified with the use of genomewide association 
studies explain only a small amount of the expected 
contribution to the risk of coronary disease. The 
use of arrays of high-density single-nucleotide poly-
morphisms (SNPs) in candidate genes for cardio-
vascular disease may help elucidate the genetic 
contribution to the risk of coronary disease.
A recent genomewide association study showed 
that a cluster of genes — solute carrier family 22 
member 3 (SLC22A3), lipoprotein(a)-like 2 (LPAL2), 
and lipoprotein(a) (LPA) — on chromosome 6q26–
27 was strongly associated with coronary artery 
disease, but the investigators were unable to iden-
tify the precise variants at this locus.7 The 6q26–
27 region includes the LPA gene, which encodes the 
apolipoprotein(a) component of the Lp(a) lipopro-
tein particle. An increased level of Lp(a) lipopro-
tein has been associated with an increased risk of 
coronary disease,8,9 carotid atherosclerosis, and 
stroke.9-11 Plasma levels of Lp(a) lipoprotein vary 
substantially among persons, and most of this 
variation reflects the effects of genetic variation 
in LPA.12 In particular, common copy-number 
variation within the LPA gene determines the num-
ber of kringle IV–type 2 repeats and hence the 
isoform size of apolipoprotein(a), and an inverse 
relationship has been reported between the num-
ber of repeats and Lp(a) levels. However, the ge-
netic determinants of Lp(a) lipoprotein levels and 
of isoform size are incompletely understood, as is 
the relevance of both measures for coronary artery 
disease.12
Our multicenter case–control study, called the 
Precocious Coronary Artery Disease (PROCARDIS) 
study, had four aims. First, we examined genetic 
associations in coronary artery disease, using a 
newly available chip13 that was specifically de-
signed to assay SNPs in candidate genes selected 
for their putative relevance to cardiovascular dis-
ease. Second, we assessed the associations of LPA 
gene variants with Lp(a) lipoprotein levels and 
isoform size in a large case–control study. Third, 
we replicated the associations in three independent 
studies. Finally, we assessed the extent to which 
the observed associations were explained by their 
effects on Lp(a) lipoprotein levels.
Me thods
Study Design and Oversight
This study was designed and conducted by the 
authors and funded by the British Heart Founda-
tion, the European Commission, and AstraZeneca. 
AstraZeneca had no role in the design of the study, 
in the data collection or analysis, in the writing of 
the manuscript, or in the decision to submit the 
results for publication. The authors vouch for the 
accuracy and completeness of the data and the 
analyses.
Subjects
We recruited 3145 case subjects with coronary ar-
tery disease and 3352 control subjects from four 
European countries (United Kingdom, Italy, Swe-
den, and Germany), according to prespecified cri-
teria.14,15 All case subjects had received a diagno-
sis of coronary artery disease before the age of 66 
years and also had a sibling in whom coronary 
disease had been diagnosed before the age of 66 
years (see the Methods section in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org). Using the same infrastruc-
ture, we recruited population-matched control 
subjects with no personal or sibling history of cor-
onary disease before the age of 66 years. The pro-
tocol was approved by the ethics committee at 
each participating center, and all subjects provided 
written informed consent. Blood samples were col-
lected from all subjects.
Assays
SNP genotyping was performed in case subjects 
and control subjects with the use of the HumanCVD 
BeadChip (Illumina)13 with the Infinium II assay, 
which includes 48,742 markers designed to survey 
genetic variation in approximately 2100 candidate 
genes selected for their relevance in cardiovascular 
disease (for details, see the Methods section in the 
Supplementary Appendix). The chip also includes 
SNPs in regions that have been identified by genom-
ewide association studies as susceptibility loci for 
coronary disease (e.g., chromosome 9p21).1-4
The HumanCVD BeadChip includes 40 SNPs 
from the LPA region. After SNP exclusions for a 
low call rate or minimum allele frequency, 27 SNPs 
were available for association analysis in the LPA 
region (Fig. 1, and the Methods section in the 
Supplementary Appendix).
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Lp(a) lipoprotein was measured by means of 
one latex-enhanced immunoturbidimetric assay 
(Immuno)16 in samples from case subjects that had 
been obtained in study clinics. In addition, Lp(a) 
lipoprotein was measured in a random subgroup 
of case subjects and control subjects with the use 
of a second latex-enhanced immunoturbidimetric 
assay (Randox Laboratories) on an ADVIA 1800 
autoanalyzer (Siemens).
We estimated the size of the apolipoprotein(a) 
isoform by means of immunoblotting in samples 
from case subjects and control subjects who were 
selected according to LPA genotype. Sodium dode-
cyl sulfate–agarose gel electrophoresis was used 
to fractionate the reduced plasma proteins accord-
ing to size before immunoblotting with apoli-
poprotein(a)-specific antibody.17 A quantitative 
polymerase-chain-reaction (PCR) assay with ge-
nomic DNA as the template was used to determine 
the relative number of LPA kringle IV–type 2 re-
peats in a subgroup of subjects for whom isoform 
data were available.18
Replication
We tested the replication of the associations in 
three independent populations that totaled 4846 
case subjects with coronary disease and 4594 con-
trol subjects. These independent cohorts included 
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Figure 1. Associations of Single-Nucleotide Polymorphisms (SNPs) in LPA with the Lp(a) Lipoprotein Level  
and the Risk of Coronary Disease in the PROCARDIS Cohort.
The 27 SNPs in LPA are listed in order of their effect on the level of Lp(a) lipoprotein. Sixteen SNPs that were signifi-
cantly associated with the Lp(a) lipoprotein level (P<1.0×10−6) are indicated by an a terisk. Seven SNPs that were 
also significantly associated with the level of Lp(a) lipoprotein by stepwise regression (P<4.0×10−9) are indicated 
with a dagger. The regression coefficients are for the log of the Lp(a) lipoprotein level, with the standard error (SE) 
providing a measure of the sampling variation. The boxes indicate odds ratios for coronary disease, and the horizon-
tal lines indicate 95% confidence intervals (CI) for the allele associated with an increased Lp(a) lipoprotein level for 
each of the SNPs. The associations have been adjusted for the country of origin. The size of the squares is inversely 
proportional to the sampling variance, which is influenced by the frequency of the SNP. Thus, even though SNP 
rs4708871 has the fourth highest odds ratio in the list, the low frequency of this SNP means that the sampling error 
is large (as indicated by the large confidence interval), so the association with coronary disease was not significant.
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“trio families” (families either with a proband and 
two parents or with a proband, a parent, and at 
least one sibling) from the PROCARDIS cohort19; 
case subjects with nonfatal myocardial infarction 
and control subjects from the International Study 
of Infarct Survival (ISIS) in the United Kingdom20; 
and case subjects with nonfatal myocardial infarc-
tion and control subjects from two studies of per-
sons living in the greater Stockholm area (the 
Stockholm Heart Epidemiology Program [SHEEP]21 
and the Stockholm Coronary Artery Risk Factor 
[SCARF] study22) (for details, see the Methods sec-
tion in the Supplementary Appendix).
We measured plasma levels of Lp(a) lipoprotein 
in samples obtained from subjects in the ISIS, 
SHEEP, and SCARF studies. The genotyping of two 
LPA SNPs (rs10455872 and rs3798220) was per-
formed with the use of a TaqMan platform.
Statistical Analysis
Analysis of the association of candidate genes with 
coronary disease was carried out after the exclu-
sion of SNPs with low call rates (<95%), very low 
frequency (minor allele frequency, <1%), or Hardy–
Weinberg disequilibrium in controls (P<1.0×10−6). 
Hidden relatedness was sought with the use of 
identity-by-state methods, and the identity of any 
first-degree relatives was recorded for subsequent 
analysis.
We used logistic and linear regression models, 
which allowed for familial clustering, to perform 
the association analyses. The test statistics were 
inspected for overdispersion, and the genomic 
control measure was calculated.23 Lp(a) lipopro-
tein levels were loge-transformed for regression 
analysis; study-specific standard-deviation units 
were used to allow for heterogeneity in measure-
ments between studies (for additional details, see 
the Methods section of the Supplementary Ap-
pendix).
R esult s
Study Population
Samples from 3145 case subjects in the PROCARDIS 
cohort were genotyped with the use of the Hu-
manCVD BeadChip. Among these samples were 
2200 from subjects who had received a diagnosis 
of myocardial infarction (with confirmation of the 
diagnosis based on hospital-discharge or general-
practice records for 91% of the subjects), 480 from 
subjects who had undergone coronary-artery revas-
cularization (of whom 424 had received a diagno-
sis of angina), and 465 from subjects with angina 
only. The control group included 3352 subjects 
from the PROCARDIS cohort who had no personal 
or sibling history of coronary disease before the 
age of 66 years.
Association with Coronary Disease
After quality-control filtering, 34,399 SNPs were 
used to test associations with coronary disease in 
samples from case subjects and control subjects. 
The genomic control measure λ was 1.03, indicat-
ing that the statistical modeling assumptions were 
appropriate. We identified 33 SNPs with an un-
adjusted P value of less than 1.0×10−6 (or P<0.05 
after adjustment for multiple testing), which 
mapped to three distinct chromosomal regions 
(6q26–27, 9p21, and 1p13) (Table 1 in the Sup-
plementary Appendix). The LPA locus on chro-
mosome 6q26–27 showed the strongest associa-
tions with coronary artery disease, with one SNP 
(rs10455872) having a P value of 3.4×10−15. The 
25 SNPs that mapped to 9p21 are in a region that 
previous genomewide association studies have 
shown to be associated with coronary disease1-4 
and type 2 diabetes.24,25 Similarly, the six SNPs 
that were localized to chromosome 1p13 are in a 
region that in previous genomewide association 
studies has been shown to be associated with 
coronary disease4 and levels of low-density lipo-
protein cholesterol.26,27 The complete set of as-
sociation results is available in the European 
Genome–Phenome Archive (www.ebi.ac.uk/ega/) 
under accession number EGAS00000000055.
Association with Lp(a) Lipoprotein Level
Lp(a) lipoprotein levels were measured in sam-
ples from 1822 case subjects. The median level 
was 33 mg per deciliter (interquartile range, 15 to 
89). There was a significant association between 
the Lp(a) lipoprotein level and 16 of the 27 SNPs 
that were studied at the LPA locus (P<1.0×10−6) (Ta-
ble 1). We confirmed previous evidence of a strong 
association for rs3798220 (P = 5.9×10−51),28,29 which 
explained about 8% of total (both genetic and 
individual-specific) variation in Lp(a) lipoprotein 
levels. We also found an exceptionally strong as-
sociation for rs10455872 (P =3.6×10−166), which 
explained about 25% of the variation. A joint anal-
ysis showed that rs3798220 and rs10455872 each 
conferred significant main effects that together 
explained 36% of variation in Lp(a) lipoprotein lev-
els. Subjects with one or more variant alleles at 
either SNP had an increased geometric mean Lp(a) 
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lipoprotein level (Table 2 in the Supplementary 
Appendix).
Stepwise regression identified seven SNPs, in-
cluding rs3798220 and rs10455872, that each had 
a significant association with Lp(a) lipoprotein 
levels (P<4.0×10−9) and together explained 40% of 
the total variation (Table 1). We previously mapped 
quantitative trait loci for Lp(a) lipoprotein by vari-
ance-components linkage analysis and estimated 
that about 74% of the total variation in Lp(a) lipo-
protein levels was specific to the LPA locus.30 Con-
sequently, it appears that the SNPs that were in-
Table 1. Association of LPA SNPs with the Plasma Level of Lp(a) Lipoprotein in 1822 Case Subjects in the PROCARDIS 
Cohort.*
SNP
Absolute 
Location
Relative 
Location
Risk Allele 
(Frequency)
Association with Increased Lp(a)  
Lipoprotein Level
Regression 
Coefficient for  
Lp(a) Level
SE for Regression 
Coefficient P Value
base pairs
rs3127596† 160,873,025 0 G (0.30) 0.30 0.04 1.5×10−14
rs7449650 160,877,104 4,079 G (0.67) 0.16 0.04 9.1×10−5
rs6919346†‡ 160,880,349 7,324 C (0.83) 0.43 0.05 1.6×10−16
rs3798220†‡ 160,881,127 8,102 C (0.02) 1.27 0.08 5.9×10−51
rs11751605†‡ 160,883,220 10,195 C (0.16) 0.50 0.04 5.9×10−28
rs4708871 160,889,086 16,061 T (0.93) 0.53 0.11 1.0×10−6
rs10755578† 160,889,728 16,703 G (0.48) 0.27 0.04 3.4×10−13
rs7761293 160,890,953 17,928 A (0.47) 0.18 0.04 2.3×10−6
rs9364559 160,896,138 23,113 A (0.81) 0.04 0.05 3.9×10−1
rs6415084† 160,900,320 27,295 T (0.49) 0.22 0.04 2.7×10−9
rs9365171† 160,901,726 28,701 C (0.65) 0.25 0.04 4.0×10−11
rs6923877† 160,916,787 43,762 A (0.67) 0.26 0.04 2.4×10−11
rs3798221†‡ 160,918,138 45,113 G (0.81) 0.28 0.05 2.0×10−9
rs7765781†‡ 160,927,486 54,461 G (0.67) 0.26 0.04 2.1×10−11
rs7765803† 160,927,528 54,503 G (0.67) 0.26 0.04 2.4×10−11
rs10455872†‡ 160,930,108 57,083 G (0.07) 1.18 0.04  3.6×10−166
rs9355296 160,937,983 64,958 G (0.84) 0.01 0.05 7.8×10−1
rs13202636† 160,949,718 76,693 G (0.78) 0.33 0.04 2.0×10−14
rs9355813† 160,951,162 78,137 T (0.64) 0.32 0.04 2.8×10−17
rs10945682†‡ 160,989,931 116,906 G (0.64) 0.32 0.04 1.8×10−17
rs1652507 161,002,451 129,426 T (0.84) 0.00 0.05 9.4×10−1
rs1321195† 161,004,146 131,121 G (0.86) 0.26 0.05 4.0×10−7
rs783149 161,008,908 135,883 C (0.84) 0.00 0.05 9.7×10−1
rs1084651 161,009,807 136,782 A (0.16) 0.01 0.05 8.4×10−1
rs1358754 161,010,510 137,485 G (0.87) 0.12 0.05 2.8×10−2
rs1358753 161,010,560 137,535 C (0.86) 0.11 0.05 3.8×10−2
rs1406888 161,011,583 138,558 T (0.53) 0.16 0.04 2.1×10−5
* The association of LPA single-nucleotide polymorphisms (SNPs) with an increased Lp(a) lipoprotein level is shown by 
a regression coefficient and standard error (SE) for each SNP. Lp(a) lipoprotein levels were first log-transformed to re-
duce skewness and then scaled as study-specific SD units to allow for heterogeneity among the studies.
† A P value of less than 1.0×10−6 was considered to indicate a significant association with the Lp(a) lipoprotein level (as 
found in 16 SNPs).
‡ A P value of less than 4.0×10−9 (as calculated by stepwise regression) was considered to indicate a significant associa-
tion with the Lp(a) lipoprotein level (as found in seven SNPs, which together explained 40% of the total variation).
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cluded in our study captured more than half the 
quantitative genetic variation encoded by LPA.
Association between Lp(a) Lipoprotein Level 
and Coronary Disease
Variants at the LPA locus that were associated with 
increased effects on Lp(a) lipoprotein levels tended 
to be associated with increased effects on the risk 
of coronary disease (Fig. 1). In particular, the 
rs3798220 and rs10455872 SNPs, which were most 
strongly associated with Lp(a) lipoprotein levels, 
were most strongly associated with the risk of 
coronary disease.
Replication of Association
We studied independent populations to test for 
replication of the associations of SNPs rs3798220 
and rs10455872 with both circulating Lp(a) lipo-
protein levels and coronary disease. With respect 
to Lp(a) lipoprotein, data were available for 500 
case subjects and 627 control subjects in the ISIS 
study and for 1151 case subjects and 1506 control 
subjects in the SHEEP and SCARF studies. After 
standardization for differences in the assay meth-
ods, there was little evidence of heterogeneity of 
the effects of each allele on Lp(a) lipoprotein lev-
els in the three populations (Fig. 2, and Table 2 
in the Supplementary Appendix).
With respect to coronary disease, data were 
available for 1259 trio families in the PROCARDIS 
cohort, for 2068 case subjects and 1484 control 
subjects in the ISIS study, and for 1519 case sub-
jects and 1851 control subjects in the SHEEP and 
SCARF studies. The two SNPs were associated 
with coronary risk in these replication cohorts, 
although the association was somewhat weaker 
than that observed in the PROCARDIS cohort (Fig. 
2). A meta-analysis of all four studies, involving 
nearly 8000 case subjects with coronary disease, 
provided an estimated odds ratio for coronary dis-
ease of 1.47 (95% confidence interval [CI], 1.35 to 
1.60) for the rs10455872 SNP and 1.68 (95% CI, 
1.43 to 1.98) for the rs3798220 SNP.
LPA Genotype Score and Coronary Disease
Maximum likelihood analysis predicted that the 
rs3798220 and rs10455872 SNPs formed three hap-
lotypes with frequencies (0.885 for T→A, 0.093 for 
T→G, and 0.023 for C→A) that were very close to 
the frequencies expected for alleles in linkage equi-
librium (with no subjects simultaneously homozy-
gous for the variant alleles at both SNPs). Hence, 
the information on coronary risk that was encoded 
by rs3798220 and rs10455872 was combined into 
a single LPA genotype score with levels 0, 1, and 
2 (or more) that corresponded to the sum of vari-
ant alleles (C for rs3798220 and G for rs10455872) 
in either of the two SNPs.
The odds ratio for coronary disease in subjects 
in the PROCARDIS cohort was 1.73 (95% CI, 1.51 
to 1.98) with one variant allele and 4.87 (95% CI, 
2.80 to 8.48) with two or more variant alleles. 
The score showed a strong association with coro-
nary disease under an allele-dose risk model 
(P = 2.4×10−21), with an odds ratio of 1.81 (95% CI, 
1.60 to 2.04) per variant allele. The association 
between these LPA variants and the risk of coro-
nary disease in subjects in the PROCARDIS cohort 
correlated with the effects of these variants on 
Lp(a) lipoprotein levels (Fig. 3).
We also examined the effects of the LPA geno-
type score on Lp(a) lipoprotein levels and on the 
risk of coronary disease in the replication cohorts 
(Fig. 2 in the Supplementary Appendix). There was 
no evidence of departure from an allele-dose risk 
model (P = 0.11) or of heterogeneity among coun-
tries of origin (P = 0.97). A meta-analysis of all the 
studies showed odds ratios for coronary disease 
of 1.51 (95% CI, 1.38 to 1.66) for one LPA variant 
allele and of 2.57 (95% CI, 1.80 to 3.67) for two 
or more alleles.
Independence of Known Risk Factors
In contrast with previous studies that reported a 
positive association between the Lp(a) lipoprotein 
level and coronary disease only in patients with 
elevated levels of low-density lipoprotein (LDL) cho-
lesterol,31 there was no significant heterogeneity 
of the odds ratio for coronary disease among sub-
groups of patients with various LDL cholesterol 
levels (Fig. 3 in the Supplementary Appendix). There 
was also no heterogeneity in the effects of the LPA 
genotype score on the risk of coronary disease ac-
cording to the level of high-density lipoprotein 
(HDL) cholesterol, age, sex, presence or absence 
of a history of myocardial infarction, body-mass 
index, presence or absence of diabetes mellitus or 
hypertension, and smoking status. The two SNPs 
alone or combined in the genotype score showed 
little consistent evidence of an association with 
blood levels of lipids or inflammatory markers in 
a subgroup of control subjects in the PROCARDIS 
cohort who were not taking a statin drug (Table 3 
in the Supplementary Appendix).
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Association with Apolipoprotein(a) Size
The rare alleles of both the rs10455872 and 
rs3798220 SNPs were each correlated with a small-
er apolipoprotein(a) isoform (as measured by West-
ern blotting) and a lower copy number (as mea-
sured with a quantitative PCR assay) (Fig. 4). There 
was very little variation in the number of kringle 
IV–type 2 repeats for chromosomes carrying the 
variant rs10455872 allele, which suggested that this 
SNP tags a clade of short isoform alleles with 17 
to 20 repeats (Fig. 4A). There was a similar pattern 
for chromosomes carrying the variant rs3798220 
allele, which suggested that this SNP tags a clade 
of isoform alleles with 19 to 21 repeats.
Coronary Disease Association Adjusted  
for Lp(a) Lipoprotein Level
We also measured levels of Lp(a) lipoprotein in a 
random subgroup of 1578 case subjects and 1726 
control subjects in the PROCARDIS cohort, using 
a Siemens autoanalyzer. In the case subjects, the 
correlation between the Lp(a) lipoprotein level and 
the result of the Immuno immunoturbidimetric 
assay was 0.94. The median Lp(a) lipoprotein level 
was 15.1 mg per deciliter (interquartile range, 7.2 
to 42.9) in case subjects and 10.3 mg per deciliter 
(interquartile range, 5.2 to 24.7) in control sub-
jects (P<0.001). In a meta-analysis of 3137 sub-
jects with coronary disease for whom Lp(a) lipo-
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Figure 2. Replication of the Association of Single-Nucleotide Polymorphisms (SNPs) in LPA with Lp(a) Lipoprotein Levels and the Risk  
of Coronary Disease in Independent Populations, as Compared with the PROCARDIS Cohort.
The results of replication testing are shown for the ssociations between two variants that were strongly linked with an increased level of 
Lp(a) lipoprotein in the PROCARDIS cohort — rs10455872 and rs3798220 — in three independent populations: case subjects with non-
fatal myocardial infarction and control subjects from two studies of persons living in the greater Stockholm area, the Stockholm Heart 
Epidemiology Program (SHEEP) and the Stockholm Coronary Artery Risk Factor (SCARF) study; case subjects with nonfatal myocardial 
infarction and control subjects from the International Study of Infarct Survival (ISIS); and PROCARDIS trio families (families either with 
a proband and two parents or with a proband, a parent, and at least one sibling). The values are regression coefficients and 95% confi-
dence intervals (CIs) for Lp(a) lipoprotein levels. Levels were first log-transformed to reduce skewness and then scaled as study-specific 
SD units to allow for heterogeneity among the studies. The odds ratios (squares, with the size inversely proportional to the sampling 
variance) are for the associations of the two SNPs with the risk of coronary disease in the various studies. The combined odds ratios and 
95% confidence intervals are indicated by the diamonds. The associations with Lp(a) lipoprotein levels have been adjusted for country, 
age, and sex. For the heterogeneity data, df denotes degree of freedom. NA denotes missing data for trio families.
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protein levels were available, the LPA genotype score 
was strongly associated with the risk of coronary 
disease (odds ratio, 1.52; 95% CI, 1.36 to 1.72) 
(Fig. 4 in the Supplementary Appendix). After ad-
justment for the Lp(a) lipoprotein level, the asso-
ciation between the LPA genotype score and the 
risk of coronary disease was abolished (odds ratio, 
1.02; 95% CI, 0.88 to 1.18).
Discussion
In this study, we identified risk loci for coronary 
disease by using a novel gene chip consisting of 
48,742 SNPs for 2100 candidate genes that were 
selected for their potential relevance to coronary 
disease. With this gene chip, we confirmed the pre-
vious identification of three chromosomal regions 
that were correlated with the risk of coronary dis-
ease: 6q26–27, 9p21, and 1p13. Since the 6q26–27 
region includes the LPA gene, we then used com-
prehensive SNP typing to characterize the spec-
trum of variation at the LPA locus and showed the 
independent relevance of several variants at the 
LPA locus for both the Lp(a) lipoprotein level and 
the risk of coronary disease.
Two common variants at rs10455872 and 
rs3798220 together explained 36% of the total 
variation in the Lp(a) lipoprotein level and were 
independently associated with an increased risk of 
coronary disease. We also found that the effects 
of the LPA variants on the risk of coronary disease 
correlated with the effects on the Lp(a) lipoprotein 
level. The linear dose–response relationship of the 
LPA variants with both the Lp(a) lipoprotein level 
and the risk of coronary disease provided com-
pelling support for a causal role of an elevated 
plasma level of Lp(a) lipoprotein in the risk of 
coronary disease.
The rs3798220 SNP encodes a nonsynonymous 
variant in LPA. The frequency of this high-risk vari-
ant is about 2%. This SNP has previously been re-
ported to have a strong association with the Lp(a) 
lipoprotein level,28,29 a moderate association with 
the LDL cholesterol level,26 and a tentative asso-
ciation with the risk of coronary disease.28,29 Thus, 
our study, which involved nearly 8000 case sub-
jects with coronary disease, provides a more de-
finitive estimate of the strength of the associa-
tion between rs3798220 and the risk of coronary 
disease. Furthermore, a haplotype analysis of Brit-
ish control genotype data (available at www.wtccc 
.org.uk) showed that rs3798220 had a strong cor-
relation (r2 = 0.86) with a four-SNP haplotype 
(CCTC; approximate frequency, 2%), which would 
explain and refine part of the recently reported 
association between the SLC22A3–LPAL2–LPA gene 
cluster and coronary disease.7
The rs10455872 SNP maps to intron 25 in the 
LPA gene. The allele frequency of the high-risk vari-
ant is about 7%. Previous studies of Lp(a) lipopro-
tein levels and the risk of coronary disease did not 
measure rs10455872 (which was poorly tagged in 
genomewide SNP arrays) and thus did not iden-
tify the strong associations with this SNP.
The SNPs that were included in our study ap-
peared to capture more than half the genetic 
variation encoded in the LPA locus in Lp(a) lipo-
protein levels, a higher rate than that previously 
reported for a pentanucleotide variant in the pro-
moter32,33 or for other SNPs identified by genome-
wide association studies.34 Variation in isoform 
size is believed to influence plasma levels through 
a direct mechanism involving protein secretory 
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Figure 3. Association of the LPA Genotype Score  
with the Lp(a) Lipoprotein Level and the Risk  
of Coronary Disease in the PROCARDIS Cohort.
The odds ratios (squares, with the size inversely pro-
portional to the sampling variation) are for the associa-
tion of the LPA genotype score (no variant alleles, one 
variant allele, or two variant alleles) with the risk of 
coronary dise se, as me sured with the use of “float-
ing absolute risks” which summarize the sampling 
variation for the three genotype scores without the se-
lection of an arbitrary baseline genotype score. The 
vertical lines indicate 95% confidence intervals.
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pro cesses.35,36 Both the rs10455872 and rs3798220 
variants were inversely correlated with kringle IV–
type 2 repeats and appear to tag clades of short 
isoform alleles. Thus, the SNP associations are 
strongly dependent on kringle-repeat polymor-
phism.
The mechanism by which an increased level of 
Lp(a) lipoprotein increases the risk of coronary 
disease is less well understood; it may involve LDL 
lipoprotein cholesterol,26 the inhibition of conver-
sion of plasminogen to plasmin,37 the inhibition 
of the expression of tissue factor,38 or the carriage 
of proinflammatory oxidized phospholipids.39 We 
found no significant association between either 
rs10455872 or rs3798220 and the plasma level of 
apolipoprotein B, fibrinogen, or C-reactive protein.
Our results extend the findings of a recent 
Danish study of kringle IV–type 2 repeats and the 
risk of coronary disease.40 In that study, the krin-
gle IV–type 2 genetic variation, as estimated with 
a quantitative PCR assay (which averaged the two 
alleles), explained 22% of the variation in the Lp(a) 
lipoprotein level; in 599 case subjects with coro-
nary disease, the association between kringle re-
peats and disease was partially attenuated by 
adjustment for the Lp(a) lipoprotein level. By con-
trast, our two-SNP LPA genotype score explained 
36% of the variation in the Lp(a) lipoprotein level, 
and the association between LPA and the risk of 
coronary disease was abolished after adjustment 
for the Lp(a) lipoprotein level in a meta-analysis 
of 3137 subjects with coronary disease — find-
ings that are consistent with a causal role of an 
increased Lp(a) lipoprotein level in coronary 
disease.
In conclusion, we have identified two common 
SNPs in LPA that correlate with both the Lp(a) li-
poprotein level and the risk of coronary disease. 
These SNPs explain 36% of the variation in the 
Lp(a) lipoprotein level. One in six persons carries 
a variant LPA allele and thus has a risk of coronary 
disease that is increased by a factor of 1.5.
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Figure 4. Number of Kringle IV–Type 2 Repeats, According to the Number 
of LPA Variants and as Compared with a Reference Set.
Panel A shows the median number of kringle IV–type 2 repeats, as identi-
fied on immunoblotting, in two LPA variants that were strongly linked with 
an increased level of Lp(a) lipoprotein in the PROCARDIS cohort — 
rs10455872 and rs3798220 — according to the number of variant alleles. 
The shorter-isoform alleles (with a lower repeat number) are represented 
by squares, and longer-isoform alleles (with a igher repeat number) are 
represented by triangles. The number of kringle IV–type 2 repeats was esti-
mated from the size of the apolipoprotein(a) band on immunoblotting. 
Panel B shows the ratio of the median number of kringle IV–type 2 repeats 
in each sample to the number in a reference set of pooled samples, as 
measured on quantitative polymerase-chain-reaction assay, according to 
the number of variant alleles. The vertical lines indicate interquartile ranges.
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